Clinical Trial Update: Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Brentuximab Vedotin in Chinese participants with relapsed/refractory CD30-positive Hodgkin lymphoma or systemic anaplastic larg…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Disease
• Lymphoma Large-cell Anaplastic

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Takeda | Conditions: Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic | Phase 2 | Status: COMPLETED | Results posted: 2019-09-06